Comparison of idarubicin and daunorubicin and their main metabolites regarding intracellular uptake and effect on sensitive and multidrug-resistant HL60 cells

Cancer Chemotherapy and Pharmacology

Volumn 38, Issue 5, 1996, Pages 476-480

  Tidefelt, Ulf ^a   Prenkert, Malin ^a   Paul, Christer ^b  

^a ÖREBRO MEDICAL CENTRE HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Daunorubicinol; Idarubicin; Idarubicinol; In vitro effect; Intracellular uptake

Indexed keywords

DAUNORUBICIN; DAUNORUBICINOL; DRUG METABOLITE; IDARUBICIN; IDARUBICINOL;

ARTICLE; CELL STRAIN HL 60; CONTROLLED STUDY; DRUG UPTAKE; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CELL DIVISION; DAUNORUBICIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE; HL-60 CELLS; HUMANS; IDARUBICIN;

EID: 0029778269     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050514     Document Type: Article

References (26)

1. Arcamone F, DiMarco A, Casazza A (1978) Chemistry and pharmacology of new antitumor anthracyclines. In: Umezava H, et al. (eds) Advances in cancer chemotherapy. Scientific Society Press, Tokyo/University Park Press, Baltimore, pp 297-312
2. Baurain R, Masquelier M, Peterson C, Deprez-de Campeneere D, Trouet A (1978) Quantitative determination of intracellular concentrations of daunorubicin and adriamycin and their main metabolites by high-pressure liquid chromatography. In: Siegenthaler W. Luethy R (eds) Current chemotherapy. Proceedings of the 10th International Congress of Chemotherapy, vol 2. Am Soc Microbiol. Washington, DC, p 1130
3. Benjamin RS, Riggs CE, Bachur NR (1973) Pharmacokinetics and metabolism of adriamycin in man. Clin Pharmacol Ther 14:592-600
4. Berman E (1993) A review of idarubicin in acute leukemia. Oncology 10:91-98
5. Berman E, McBride M (1992) Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. Blood 79:3267-3273
6. Berman E, Heller G, Santorsa J, McKenzie S, Gee T, Kempin S, Gulati S, Andreeff M, Kolitz J, Gabrilove J (1991) Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 77:1666-1674
7. Boiron J-M, Belloc F, Montastruc M, Cony-Makhoul P, Dumain P, Marit G, Mahon F-X, Puntous M, Lopez F, Lacombe F, Reiffers J (1994) Flow cytometric study of idarubicin and daunorubicin accumulation and the effect of verapamil in leukemic cell lines and fresh cells from patients with acute non-lymphoblastic leukemia. Leuk Res 18:313 318
8. Carella AM, Carlier P, Pungolino E, Resegotti L, Liso V, Stasi R, Montillo M, Iacopino P, Mirto S, Pagano L, Leoni F, Martelli FM, DiRaimondo F, Porcellini A, deRiu L, Nosari AM, Cimino R, Damasio E, Miraglia E, Kioritoni G, Ricciuti F, Carotenuto M, Longinotti M, Defazio D, Fazi P, Mandelli F (1993) Idarubicin in combination with intermediate-dose cytarabine and VP-16 in the treatment of refractory or rapidly relapsed patients with acute myeloid leukemia. Leukemia 7:196-199
9. Cersosimo RJ (1992) Idarubicin: an anthracycline antineoplastic agent. Clin Pharm 11:152-167
10. Jönsson K, Dahlberg N, Tidefelt U, Paul C, Andersson G (1995) Characterization of an anthracycline-resistant human promyelocyte leukemia (HL-60) cell line with an elevated mdr-1 gene expression. Biochem Pharmacol 49:755-762
11. Kuffel MJ, Reid JM, Ames MM (1992) Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture. Cancer Chemother Pharmacol 30:51-57
12. Limonta M, Biondi A, Giudici G, Specchia G, Catapano C, Masera G, Barbui T, D'Incalci M (1990) Cytotoxicity and DNA damage caused by 4-demethoxydaunorubicin and its metabolite 4-demethoxy-13-hydroxydaunorubicin in human acute myeloid leukemia cells. Cancer Chemother Pharmacol 26:340-342
13. Lowry OM, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the folin phenol reagent. Biol Chem 193:265-275
14. Mandelli F, Petti MC, Ardia A, DiPietro N, DiRaimondo F, Ganzina F, Falconi E, Geraci E, Ladogana S, Latagliata R, Malleo C, Nobile F, Petti N, Rotoli B, Specchia G, Tabilio A, Resegotti L (1991) A randomized clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukemia. Eur J Cancer 27:750-755
15. McGrath T, Center MS (1987) Adriamycin resistance in HL60 cells in the absence of detectable P-glycoprotein. Biochem Biophys Res Commun 145: 1171 1176
16. Paul C, Baurain R, Gahrton G, Peterson C (1980) Determination of daunorubicin and its main metabolites in plasma, urine and leukemic cells in patients with acute myeloblastic leukemia. Cancer Lett 9:263-269
17. Paul C, Liliemark J, Tidefelt U, Gahrton G, Peterson C (1989) Pharmacokinetics of daunorubicin and doxorubicin in plasma and leukemic cells from patients with acute nonlymphoblastic leukemia. Ther Drug Monit 11:140 148
18. Reid JM, Pendergrass TW, Krailo MD, Hammond GD, Ames MM (1990) Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: Children's Cancer Study Group report. J Pediatr Oncol Nurs 7:117 120
19. Rhedin A-S, Tidefelt U, Jönsson K, Lundin A, Paul C (1993) Comparison of a bioluminescence assay with differential staining cytotoxicity for cytostatic drug testing in vitro in human leukemic cells, Leuk Res 17:271-276
20. Robert J, Rigal-Huguet F, Harousseau JL, Pris J, Huel S, Reiffers J, Hurteloup P, Tamassia V (1987) Pharmacokinetics of idarubicin after daily intravenous administration in leukemic patients. Leuk Res 11:961-964
21. Robert J, Rigal-Huguet F, Hurteloup P (1992) Comparative pharmacokinetic study of idarubicin and daunorubicin in leukemia patients. Hematol Oncol 10: 111-116
22. Speth PAJ, Loo FAJ van de, Linssen PCM, Wessels HMC, Haanen C (1986) Plasma and leukemic cell pharmacokinetics of oral and intravenous 4-demethoxydaunorubicin. Clin Pharmacol Ther 40:643-649
23. Tidefelt U, Sundman-Engberg B, Paul C (1989) Comparison of the intracellular pharmacokinetics of doxorubicin and 4′-epidoxorubiein in patients with acute leukemia. Cancer Chemother Pharmacol 24:225-229
24. Tidefelt U, Sundman-Engberg B, Paul C (1994) Comparison of the intracellular pharmacokinetics of daunorubicin and idarubicin in patients with acute leukemia. Leuk Res 18:293-297
25. Vogler WR, Velcz-Garcia E, Weiner RS, Flaum MA, Bartolucci AA, Omura GA, Gerber MC, Banks PL (1992) A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: Southeastern Cancer Study Group study. J Clin Oncol 10:1103-1111
26. Wiernik PH, Case DC Jr, Arlin ZA, Penman PO, Todd MB, Ritch PS, Enck RE, Weitberg AB (1992) Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 79:313-319